Makiko Yoshida1, Taku Obara1,2,3, Saya Kikuchi1, Michihiro Satoh4, Yoshihiko Morikawa5, Nobuhiro Ooba6, Hiroaki Yamaguchi1, Nariyasu Mano1. 1. Tohoku University Hospital, Sendai, Japan. 2. Tohoku University Tohoku Medical Megabank Organization Sendai, Japan. 3. Tohoku University Graduate School of Medicine, Sendai, Japan. 4. Tohoku Medical and Pharmaceutical University, Sendai, Japan. 5. Tokyo Metropolitan Children's Medical Center, Fuchu, Japan. 6. Nihon University School of Pharmacy, Funabashi, Japan.
Abstract
Objective: The aim of this study is to investigate the trend of prescription drugs for children with ADHD in Japan. Method: Using health insurance claims data of 3,672,951 people between January 2005 and December 2015, we investigated the trend of prescription drugs for 7,856 children with ADHD. Results: After approval in 2007, the proportion of prescriptions for methylphenidate-osmotic-controlled release oral delivery system tablets was 31.4% in 2009 (adjusted odds ratio [AOR] = 2.72; 95% confidence interval [CI] = [2.12, 3.51]) and reached a plateau approximately after 2009 (AOR = 0.96; 95% CI = [0.94, 0.98]). The proportion of prescriptions for atomoxetine increased from 6.1% in 2008 to 21.8% in 2014 (AOR = 1.12; 95% CI = [1.13, 1.18]). The proportion of prescriptions for aripiprazole and ramelteon increased (all trend p < .001). Conclusion: Prescriptions of drugs for children with ADHD have changed. We need to monitor the safety of ADHD medications among children with ADHD.
Objective: The aim of this study is to investigate the trend of prescription drugs for children with ADHD in Japan. Method: Using health insurance claims data of 3,672,951 people between January 2005 and December 2015, we investigated the trend of prescription drugs for 7,856 children with ADHD. Results: After approval in 2007, the proportion of prescriptions for methylphenidate-osmotic-controlled release oral delivery system tablets was 31.4% in 2009 (adjusted odds ratio [AOR] = 2.72; 95% confidence interval [CI] = [2.12, 3.51]) and reached a plateau approximately after 2009 (AOR = 0.96; 95% CI = [0.94, 0.98]). The proportion of prescriptions for atomoxetine increased from 6.1% in 2008 to 21.8% in 2014 (AOR = 1.12; 95% CI = [1.13, 1.18]). The proportion of prescriptions for aripiprazole and ramelteon increased (all trend p < .001). Conclusion: Prescriptions of drugs for children with ADHD have changed. We need to monitor the safety of ADHD medications among children with ADHD.
Entities:
Keywords:
ADHD; children; proportion of prescription
Authors: Daniel Fife; Erica A Voss; Jill Hardin; Hany Rofael; Ira D Solomon; Patrick B Ryan; Paul Stang Journal: Neuropsychopharmacol Rep Date: 2021-06-28